Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$0.67
+3.9%		$1.19
$0.57
▼
$2.44
$26.33M0.482.07 million shs113,573 shs
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
$4.59
-5.6%		$4.89
$3.71
▼
$7.75
$114M0.6119,468 shs152,927 shs
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
$0.86
+0.8%		$0.85
$0.73
▼
$1.51
$108.38M1.13652,167 shs672,836 shs
YARW
Yarrow Bioscience
$37.00
-2.6%		$0.00
$14.02
▼
$46.95
$101.45M1.9630,041 shs39,377 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
+3.94%-7.60%-42.69%-60.39%-63.44%
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
-5.56%-5.75%+18.60%-4.77%-30.03%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
+0.78%+1.60%+13.97%-17.63%-19.19%
YARW
Yarrow Bioscience
-2.63%+1.59%+21.51%+3,699,999,900.00%+3,699,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$0.67
+3.9%		$1.19
$0.57
▼
$2.44
$26.33M0.482.07 million shs113,573 shs
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
$4.59
-5.6%		$4.89
$3.71
▼
$7.75
$114M0.6119,468 shs152,927 shs
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
$0.86
+0.8%		$0.85
$0.73
▼
$1.51
$108.38M1.13652,167 shs672,836 shs
YARW
Yarrow Bioscience
$37.00
-2.6%		$0.00
$14.02
▼
$46.95
$101.45M1.9630,041 shs39,377 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
+3.94%-7.60%-42.69%-60.39%-63.44%
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
-5.56%-5.75%+18.60%-4.77%-30.03%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
+0.78%+1.60%+13.97%-17.63%-19.19%
YARW
Yarrow Bioscience
-2.63%+1.59%+21.51%+3,699,999,900.00%+3,699,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
1.00
SellN/AN/A
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
2.71
Moderate Buy$15.33234.06% Upside
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
2.67
Moderate Buy$5.00483.70% Upside
YARW
Yarrow Bioscience
3.00
Buy$58.0056.76% Upside

Current Analyst Ratings Breakdown

Latest BYSI, COYA, ONCY, and YARW Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/24/2026
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/24/2026
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$12.00
8/19/2026
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$5.00
8/12/2026
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$14.00
8/3/2026
YARW
Yarrow Bioscience
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold ➝ Buy$58.00
7/28/2026
YARW
Yarrow Bioscience
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
7/17/2026
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/14/2026
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/13/2026
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/8/2026
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/25/2026
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 8/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$1.75M15.63$0.12 per share5.63($0.88) per share-0.76
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
$7.95M13.54N/AN/A$1.84 per share2.49
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/AN/AN/AN/A($0.05) per shareN/A
YARW
Yarrow Bioscience
$570K173.32N/AN/A$8.26 per share4.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$1.01M-$0.12N/AN/AN/AN/AN/A-28.88%11/12/2026 (Estimated)
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
-$21.23M-$1.07N/AN/AN/A-270.22%-52.05%-46.34%11/11/2026 (Estimated)
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-$28.76M-$0.34N/AN/AN/AN/A-2,185.97%-442.99%11/11/2026 (Estimated)
YARW
Yarrow Bioscience
-$26.48M-$14.64N/AN/AN/A-4,726.21%-84.40%-77.68%N/A

Latest BYSI, COYA, ONCY, and YARW Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$0.54-$0.02+$0.52-$0.02$8.77 millionN/A
8/12/2026Q2 2026
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-$0.0538-$0.08-$0.0262-$0.08N/AN/A
8/11/2026Q2 2026
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
-$0.3457-$0.28+$0.0657-$0.28$0.13 million$0.24 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/AN/A
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
N/AN/AN/AN/AN/A
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/AN/AN/AN/AN/A
YARW
Yarrow Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A
0.70
0.70
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
N/A
13.40
13.40
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/A
1.35
1.35
YARW
Yarrow Bioscience
N/A
15.26
15.26

Institutional Ownership

CompanyInstitutional Ownership
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
40.29%
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
39.75%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
6.82%
YARW
Yarrow Bioscience
83.78%

Insider Ownership

CompanyInsider Ownership
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
29.31%
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
6.10%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
0.10%
YARW
Yarrow Bioscience
3.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
8041.12 million29.07 millionOptionable
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
623.46 million22.03 millionNot Optionable
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
30127.51 million127.38 millionNot Optionable
YARW
Yarrow Bioscience
302.67 million2.59 millionN/A

Recent News About These Companies

Wall Street Zen Upgrades Yarrow Bioscience (NASDAQ:YARW) to "Hold"
August 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30975128
Analyst Maintains Buy on Yarrow Bioscience, Sees Attractive Risk-Reward with Unchanged $56 Price Target
August 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/analyst-maintains-buy-on-yarrow-bioscience-sees-attractive-risk-reward-with-unchanged-56-price-target-ratings-news?utm_source=marketbeat.com&utm_medium=referral
Yarrow Bioscience Alters Capital Structure With Warrant Exchange
July 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/yarrow-bioscience-alters-capital-structure-with-warrant-exchange?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

BeyondSpring stock logo

BeyondSpring NASDAQ:BYSI

$0.67 +0.03 (+3.94%)
As of 08/28/2026 04:00 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Coya Therapeutics stock logo

Coya Therapeutics NASDAQ:COYA

$4.59 -0.27 (-5.56%)
As of 08/28/2026 04:00 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Oncolytics Biotech stock logo

Oncolytics Biotech NASDAQ:ONCY

$0.86 +0.01 (+0.78%)
As of 08/28/2026 04:00 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Yarrow Bioscience NASDAQ:YARW

$37.00 -1.00 (-2.63%)
As of 08/28/2026 03:59 PM Eastern

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas